Cardiovascular Effects of Etomidate With Emphasis on Regional Myocardial Blood Flow and Performance

Prakash, Om; Dhasmana, K. M.; Verdouw, Pieter D.; Saxena, Pramod R.

doi:10.1093/bja/53.6.591

Cited by 29 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, although most intravenous anaesthetic agents will reduce ICP there is always the danger of cardiovascular depression and a fall in MAP which may reduce CPP. Various workers have demonstrated minimal cardiovascular effects when etomidate is used as an induction agent in man [9,11,21 ], although Prakash et al have demonstrated a dose dependent depression of cardiac output, arterial pressure and left ventricular dp/dt max when etomidate infusions were administered to pigs [18]. These effects were relatively minor at a dose equivalent to that required for surgical anaesthesia, but cardiovascular depression might be anticipated in patients given higher doses of etomidate.…”

Section: Discussionmentioning

confidence: 99%

The use of etomidate in the management of severe head injury

et al. 1983

View full text Add to dashboard Cite

The effects of continuous and supplementary bolus dose administration of etomidate have been investigated in ten artificially ventilated patients in traumatic coma. Continuous infusion of etomidate (5-25 micrograms/kg/min) proved to be a practical and safe means of sedating these patients and appeared to control moderately elevated ICP. Additional bolus doses of etomidate (0.2 mg/kg) always reduced acutely elevated ICP (greater than 20 mmHg), which fell by a mean of 33%. However, MAP usually fell, and occasionally serious hypotension occurred. Of a total of 61 bolus dose administrations which were analysed, CPP rose on 40 occasions, fell on 19 and was unchanged twice. There was a weak correlation between the control level of ICP and the magnitude of the fall in ICP in response to the bolus dose of etomidate (r = 0.51, p less than 0.001). Bolus doses of etomidate given just before noxious stimulation, for example chest physiotherapy, prevented or limited the expected rise in ICP (with bolus mean change in ICP = -2.7 +/- 6.9 mmHg, without bolus mean change in ICP = +7.0 +/- 6.4 mmHg). Again MAP tended to fall following the bolus dose. Overall CPP tended to fall slightly following stimulation whether or not a bolus dose was administered (-3.2 +/- 11.1 mmHg and -4.9 +/- 11.5 mmHg respectively). However, when the bolus of etomidate was not given, occasional dramatic and dangerous rises in ICP were seen, in spite of the infusion, during which CPP fell to critical levels. This very rarely occurred when the bolus had been given. Furthermore, serious episodes of hypotension in response to etomidate administration appeared to occur mainly in patients who were relatively hypo-volaemic.

show abstract

Section: Discussionmentioning

confidence: 99%